ESTRELLA IMMUNOPHARMA, INC. Investing Cash Flow
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Investing Cash Flow of $4.96 million for the 12-month period ending 2024-06-30, per its 10-KT filed 2025-03-25.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2025-03-25
- ESTRELLA IMMUNOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2023-12-31 was $5.07M.
- ESTRELLA IMMUNOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2023-09-30 was -$112.30K.
- ESTRELLA IMMUNOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2024 was $4.96M.
- ESTRELLA IMMUNOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$273.07K.
- ESTRELLA IMMUNOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2022 was $36.17M.
- ESTRELLA IMMUNOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2021 was -$45.19M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $5.07M derived: sum of 3 quarters · filed 2025-03-25 | $4.96M 10-KT · filed 2025-03-25 |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $5.07M derived: sum of 2 quarters · filed 2024-05-15 | $4.96M 10-Q · filed 2024-05-15 | $4.98M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $5.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $4.96M 10-Q · filed 2024-02-14 | $4.98M derived: sum of 3 quarters · filed 2024-11-14 | $5.06M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-09-30 | -$112.30K 10-Q · filed 2024-11-14 | -$90.87K derived: sum of 2 quarters · filed 2024-11-14 | -$13.09K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $21.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $99.20K 10-Q · filed 2023-08-01 | -$273.07K 10-K · filed 2024-09-27 | |
| 2023-03-31 | $77.77K 10-Q · filed 2023-05-18 | -$136.53K 10-Q · filed 2024-05-15 | ||
| 2022-12-31 | $36.17M 10-K · filed 2023-03-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$42.00M derived: sum of 2 quarters · filed 2023-03-14 | -$45.19M 10-K · filed 2023-03-14 | |
| 2021-09-30 | -$42.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$45.19M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$3.19M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |